All tracked trials

Phase 2 and Phase 3 cancer trials run by companies on the Nasdaq or New York Stock Exchange.

1,669 trials · most recently edited first

ABBVAbbVie
1Calm
A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma
Not started yetPhase 3520 patientsMain results: Feb 2033
MGTXMeiraGTx, LLC
0Calm
A Study of AAV2-hAQP1 Gene Therapy in Participants With Radiation-Induced Late Xerostomia
Running, no new patientsPhase 2290 patientsMain results: Jun 2027
NVSNovartis Pharmaceuticals
5Calm
A Study of 177Lu-FAP-2286 in Advanced Solid Tumors
Signing up patientsPhase 1/2222 patientsMain results: Dec 31, 2027
ONCBeiGene
2Calm
A Study Investigating the Efficacy and Safety of Alcestobart (LBL-007) Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer
Running, no new patientsPhase 1/2113 patientsMain results: May 23, 2025
AAPGAscentage Pharma Group Inc.
0Calm
A Study of Olverembatinib in SDH-deficient GIST.
Signing up patientsPhase 340 patientsMain results: Mar 31, 2027
PFESeagen, a wholly owned subsidiary of Pfizer
0Calm
A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer
Running, no new patientsPhase 3466 patientsMain results: Jun 29, 2023
PFESeagen, a wholly owned subsidiary of Pfizer
0Calm
A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer
Running, no new patientsPhase 3762 patientsMain results: May 18, 2026
AMGNAmgen
2Calm
A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation
Signing up patientsPhase 214 patientsMain results: Jul 1, 2028
MRKMerck Sharp & Dohme LLC
5Calm
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)
Running, no new patientsPhase 3342 patientsMain results: Apr 24, 2026
AZNAstraZeneca
0Calm
An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC
Signing up patientsPhase 3915 patientsMain results: Sep 11, 2030
LLYEli Lilly and Company
0Calm
A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer
Running, no new patientsPhase 2309 patientsMain results: Feb 16, 2018
PFESeagen, a wholly owned subsidiary of Pfizer
0Calm
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
Signing up patientsPhase 2372 patientsMain results: Dec 11, 2026
PFESeagen, a wholly owned subsidiary of Pfizer
0Calm
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
Running, no new patientsPhase 254 patientsMain results: Jul 28, 2029
PFESeagen, a wholly owned subsidiary of Pfizer
0Calm
Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors
Running, no new patientsPhase 2350 patientsMain results: Mar 20, 2026
AMGNAmgen
2Calm
Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation
FinishedPhase 3160 patientsMain results: Jul 16, 2025
LLYEli Lilly and Company
0Calm
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
Running, no new patientsPhase 3874 patientsMain results: Jun 24, 2024
PFESeagen, a wholly owned subsidiary of Pfizer
0Calm
A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2
Running, no new patientsPhase 2120 patientsMain results: Mar 27, 2026
BDTXBlack Diamond Therapeutics, Inc.
10Calm
Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations
Running, no new patientsPhase 1/2200 patientsMain results: Nov 3, 2025
AMGNAmgen
2Calm
A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)
Running, no new patientsPhase 2222 patientsMain results: Dec 30, 2027
PFESeagen, a wholly owned subsidiary of Pfizer
0Calm
Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2
Running, no new patientsPhase 3412 patientsMain results: Jan 29, 2027
PFESeagen, a wholly owned subsidiary of Pfizer
0Calm
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
Signing up patientsPhase 3400 patientsMain results: Dec 31, 2027
GSKGlaxoSmithKline
0Calm
A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)
Running, no new patientsPhase 388 patientsMain results: Jun 30, 2026
IONSIonis Pharmaceuticals, Inc.
8Calm
FUSION: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis Participants With Fused in Sarcoma Mutations (FUS-ALS)
Running, no new patientsPhase 389 patientsMain results: Jun 17, 2026
ABBVAbbVie
1Calm
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
Running, no new patientsPhase 2185 patientsMain results: Oct 2030
AZNAstraZeneca
0Calm
AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
Signing up patientsPhase 31,100 patientsMain results: Nov 17, 2028